Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 14615 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke.DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER, BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Deans' stroke musings
Changing stroke rehab and research worldwide now.Time is Brain!Just think of all thetrillions and trillions of neuronsthateach daybecause there areeffective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.
What this blog is for:
Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group. My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html
Wednesday, January 4, 2017
Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Stem Cells in Subacute Ischemic Stroke Patients
How would these stem cells travel thru the blood brain barrier and have enough smarts to locate where needed? I see nothing here that proves anything about the efficacy of this. They don't even tell you if the stem cells survived. Placebo effect anyone? Subacute(1 week and up to 3 months) definition means spontaneous recovery still going on. Bogus research, two variables in this. http://journal.frontiersin.org/article/10.3389/fneur.2016.00228/full?
Introduction: Based on many preclinical and small
clinical trials, stem cells can help stroke patient with the
possibility of replacing the cells and supporting the remaining cells.
The aim of this study was to evaluate the safety and feasibility of bone
marrow mononuclear (BMMN) stem cell transplantation in subacute
ischemic stroke patients.
Materials and methods: Thirty-nine (n =
39) patients with subacute ischemic cerebral infarct due to large artery
occlusion in the middle cerebral artery (MCA) territory were recruited.
They were distributed into two groups: first group (n = 21)
served as an experimental group, which received intra-arterial (IA)
mononuclear stem cells (bone marrow-derived mononuclear cell), while the
other group (n = 18) served as a control group. All the patients
were evaluated clinically by National Institutes of Health Stroke
Scale, modified Rankin Scale, Barthel Index, modified and standardized
Arabic version of the Comprehensive Aphasia Test, and radiological for
Results: The stem cell-treated group showed
better improvement, but it was not significant when compared with the
non-treated group. The volume of infarction changes at the end of the
study was non-significant between both the groups. There was no, or
minimal, adverse reactions in stem cell-treated group.
Conclusion: The study results suggest that
autologous BMMN stem cell IA transplantation in subacute MCA ischemic
stroke patients is safe with very minimal hazards, but no significant
improvement of motor, language disturbance, or infarction volume was
detected in stem cell-treated group compared with the non-treated group.
Stroke represents the third cause of death, followed by
cancer and myocardial infarction. Its morbidity and mortality keep
increasing during the past few years, especially in developing countries
The prevalence of non-fatal stroke in Egypt is 5.6 per 1,000 populations (2),
and the disability-adjusted life years (the sum of life years lost as a
result of premature death and years lived with disability adjusted for
severity lost per 1,000 population) was 8 in 2003 (3).
Despite the availability of active therapies as
thrombolytic therapy and percutaneous intravascular interventions, many
patients suffering from stroke often remain disabled (4).
These post-stroke disabilities have attracted the attention of
researchers to explore more effective and safer treatments. Stem cells
offer the promise of a novel neurorestorative strategy for acute brain
injury. Recent preclinical studies in rodent stroke model using stem
cell therapy have demonstrated significant behavioral recovery and, in
some cases, reductions in lesion volume (5).
Although there are many types of stem cells, bone
marrow-derived mononuclear cells (BM-MNCs) represent one of the most
convenient types for clinical use, as they can be isolated rapidly from
autologous bone marrow without culture (6).
There are many potential mechanisms of cellular therapy
by which transplanted stem cells are able to locate to the infarcted
brain area and differentiate into neuronal and glial phenotypes; there
is evidence that cell replacement could contribute to the
reestablishment of neuronal circuits by increasing the sprouting of
nerve fibers (7).
In the experimental model of stroke, intravenous,
intra-striatal, and intra-arterial (IA) infusion of mononuclear stem
cells have improved neurological outcome through reduced apoptosis and
decreased peri-infarct inflammation and angiogenesis (8).
The aim of this study is to assess the safety and
feasibility of autologous bone marrow mononuclear (BMMN) stem cells in
managing patients suffering from large artery ischemic stroke in the
territories of middle cerebral artery (MCA) in the subacute stage. This
study was approved by the ethical committee of Faculty of Medicine,
Tanta University, Egypt.